• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    TransEnterix Announces New Training Center in EU

    2/18/21 8:45:00 AM ET
    $TRXC
    Medical/Dental Instruments
    Health Care
    Get the next $TRXC alert in real time by email

    RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced the Company has agreed to partner with the Amsterdam Skills Centre (ASC) in the Netherlands for surgical training. This site will serve surgeons and staff throughout Europe with basic and advanced training on the Senhance® Surgical System. The ASC will also provide TransEnterix with a world-class facility to engage European surgeons in technology and clinical development studies.

    “As TransEnterix continues to expand our footprint and adoption in Europe, we face a growing need to train European surgical teams on Senhance,” said Anthony Fernando, TransEnterix president and CEO. “The ASC is a world-class facility that is ideally located to meet our commercial needs. We are also pleased at the capabilities to cooperatively perform important technology and clinical development activities."

    The Senhance Surgical System is the first and only digital laparoscopic platform designed to maintain laparoscopic minimally invasive surgery standards while providing digital benefits such as haptic feedback, robotic precision, eye-sensing camera control, comfortable ergonomics, advanced instrumentation including 3 mm microlaparoscopic instruments, and reusable standard instruments to help maintain per-procedure costs similar to traditional laparoscopy. TransEnterix also recently launched the first machine vision system in robotic surgery. This first-of-its-kind augmented intelligence capability is powered by the new Intelligent Surgical Unit™ on the Senhance Surgical System.

    “Bringing the Senhance Surgical system to the ASC is a major achievement in our vision to be a leading global site for advanced surgical training in minimally invasive technology,” said Prof. Dr. Jaap Bonjer, Professor of Surgery at Amsterdam University Medical Centre and CEO of the ASC. “We believe that the future of surgery will be driven by newer technologies that enable better information guidance in real-time. The Senhance combines machine vision and learning capabilities with precision surgery while also seeking to address high healthcare costs. This technology fits very well with our mission.”

    About TransEnterix

    At TransEnterix, Inc., we are digitizing the interface between the surgeon and the patient to improve minimally invasive surgery (MIS) through a new category of care called Digital Laparoscopy. Digitizing the interface enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and allows us to address the current clinical, cognitive and economic shortcomings in surgery. The system features the first machine vision system for use in robotic surgery which is powered by the new Intelligent Surgical Unit™ (ISU™) that enables augmented intelligence in surgery. The Senhance® Surgical System brings the benefits of Digital Laparoscopy to patients around the world while staying true to the principles of value-based healthcare. Learn more about Digital Laparoscopy with the Senhance Surgical System here: https://Senhance.com/. Now available for sale in the US, the EU, Japan, Russia, and select other countries. For a complete list of indications for use, please visit: https://www.transenterix.com/indications-for-use/.

    About The Amsterdam Skills Centre

    The Amsterdam Skills Centre (ASC) offers medical specialists and other health care professionals from all over the world an innovative learning environment with 12 high-tech operating rooms, operating robots, VR-simulators, a learning platform and services to fully digitalize the OR learning experience. The ASC is developing faster, safer and more efficient training modules that enable medical specialists to handle surgical interventions in a short period of time. It is an incubator where people and resources are connected to build a New Way of Learning. Our goal is to build a global scalable, low cost and mobile learning environment which can be implemented on-site, here and in low and middle income countries. The ASC is located on the premises of Amsterdam University Medical Centers.

    Learn more at: https://www.asc.amsterdam/

    Forward-Looking Statements

    This press release includes statements relating to the Senhance Surgical System and the Company announcing its new training center at the Amsterdam Skills Center in the Netherlands. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether the ASC will be able to meet our commercial needs and whether the Senhance Surgical System technology will be able to meet the mission of the ASC. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 16, 2020 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

    Get the next $TRXC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TRXC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TRXC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Rampertab Shameze

    4 - TRANSENTERIX, INC. (0000876378) (Issuer)

    2/8/21 8:50:49 PM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    SEC Form 4: J. C. Anthony Fernando exercised 146,873 units of Common Stock at a strike of $0.00 and disposed of $214,521 worth of Common Stock (67,248 units at $3.19), increasing ownership by 143% to 135,126 units

    4 - TRANSENTERIX, INC. (0000876378) (Issuer)

    2/8/21 8:48:15 PM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    $TRXC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Asensus Surgical, Inc. Schedules Fourth Quarter and Fiscal Year 2020 Financial and Operating Results Conference Call for March 11, 2021

    RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: TRXC) (formerly TransEnterix, Inc.), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced today that it plans to release fourth quarter and fiscal year 2020 financial and operating results after the market closes on Thursday, March 11, 2021. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-855-327-6837 for domestic callers and 1-631-891-4304

    3/4/21 6:55:00 AM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    Asensus Surgical Announces FDA Clearance in General Surgery

    RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (formerly TransEnterix, Inc.) (NYSE American: TRXC) , a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, today announced the Company has received an additional FDA clearance for the Senhance Surgical System which allows for indication expansion in general surgery in the United States. Asensus Surgical's technology platform, Senhance® Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning.

    3/3/21 6:55:00 AM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    Asensus Surgical to Present at the H.C. Wainwright Virtual Global Life Sciences Conference

    RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: TRXC) (formerly TransEnterix, Inc.), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery, announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the H.C. Wainwright Virtual Global Life Sciences Conference taking place March 9 and March 10, 2021. The Company’s presentation will be available for on-demand beginning Tuesday, March 9, 2021 at 7:00 am ET. The on-demand conference presentation wil

    3/1/21 6:55:00 AM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    $TRXC
    SEC Filings

    View All

    SEC Form 8-K filed

    8-K - ASENSUS SURGICAL, INC. (0000876378) (Filer)

    3/12/21 4:31:17 PM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed

    10-K - ASENSUS SURGICAL, INC. (0000876378) (Filer)

    3/11/21 5:22:06 PM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed

    8-K - ASENSUS SURGICAL, INC. (0000876378) (Filer)

    3/3/21 4:31:01 PM ET
    $TRXC
    Medical/Dental Instruments
    Health Care

    $TRXC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - TRANSENTERIX, INC. (0000876378) (Subject)

    2/16/21 9:51:05 AM ET
    $TRXC
    Medical/Dental Instruments
    Health Care